Log in

THAT Thalia Therapeutics PLC LSE · United Kingdom

Thalia Therapeutics (THAT) news

Thalia Therapeutics PLC is a public biotech or pharmaceutical company listed on LSE under the ticker THAT, recorded under United Kingdom. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Thalia Therapeutics news

We have not published a story on Thalia Therapeutics yet. When there is news, it will appear here.

Questions about Thalia Therapeutics

What is the ticker symbol of Thalia Therapeutics?

Thalia Therapeutics PLC trades under the ticker THAT on LSE.

Where is Thalia Therapeutics listed?

Thalia Therapeutics PLC is listed on LSE.

Which country or territory is Thalia Therapeutics listed under?

Our directory records Thalia Therapeutics PLC under United Kingdom.

What does Thalia Therapeutics do?

Our directory classifies Thalia Therapeutics PLC as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Thalia Therapeutics?

The ISIN recorded for Thalia Therapeutics PLC is GB00BYW8QM32.

Does aibio.space cover Thalia Therapeutics?

aibio.space lists Thalia Therapeutics PLC among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Thalia Therapeutics?

Companies in our directory listed in the same country and business area as Thalia Therapeutics: Diaceutics Plc, Nuformix Plc, Adaptimmune Therapeutics, COMPASS Pathways Plc, HemoGenyx Pharmaceuticals Plc, Genflow Biosciences Plc.

Investor discussion: Thalia Therapeutics

Members talk about Thalia Therapeutics (THAT). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open LSE:THAT on TradingView.

Listing details

Thalia Therapeutics PLC is a public biotech or pharmaceutical company listed on LSE under the ticker THAT, recorded under United Kingdom. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Thalia Therapeutics PLC
Ticker
THAT
Listing
LSE
Country or territory
United Kingdom
Business scope
Biotechnology
ISIN
GB00BYW8QM32
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.